ClinicalTrials.gg
RecruitingNCT05965180Updated Nov 9, 2026

Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

An observational study in Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Michigan Rogel Cancer Center · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
40 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center — 7 open to participants now, 12 under way, none of them phase 3. Prostatic Neoplasms · University of Michigan Rogel Cancer Center.

Started
2023
the only one that year
Observational
3 of 36
3 open now
Primary completion
2027-10
later than 5 of 11 live
Registered
30th of 36
by date

Among the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, this one is the only one that started in 2023, is one of 3 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 30th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 40 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, or all of them as a file.
02

Study summary

In this project, we will integrate the Photoacoustic (PA) technology into a prostate biopsy procedure through a fine needle probe. The needle probe will be in the shape of a biopsy needle and compatible with the needle insertion mechanism in the transrectal ultrasound (TRUS) probe. When inserted into the prostate, the fine needle PA probe will assess the histological information in its surrounding tissue without any tissue extraction. The needle probe has been tested in prostate tissue samples and whole human prostates ex vivo.

Read the detailed description

14AUG2024- enrollment was increased to 50 subjects

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Biopsy
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with planned prostate biopsy procedures will be recruited through U-M Urology Clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Planned prostate as part of routine clinical care
  • 2) > 40 and \<80 years old

Exclusion criteria

Exclusion Criteria:

  • 1) Known history of bleeding disorders or
  • 2) Patients taking anticoagulants, no matter doses or washout time
  • 3) Known allergy to silicone material
  • 4) Unable to provide
  • 5) Either the surgeon or the patient do not think the patient will not be able to complete all parts of the study, the patient will be excluded
  • 6) Involved in other studies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Biopsy

    Patients will be identified once prostate biopsies have been scheduled. Once enrolled on trial, patients will undergo standard biopsy procedure as per clinical care. During this biopsy, research measurements will be completed using the fine needle photoacoustic probe.

    Device: Fine Needle Photoacoustic Probe

Interventions

  • DeviceFine Needle Photoacoustic Probe

    Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction

06

What researchers measure

Primary outcomes

  1. Demonstration of reliable measurements

    The primary aim of this study is to demonstrate that our fine needle PA probe can acquire reliable measurements of prostate glands. This will be indicated by a signal-to-noise ratio of the measurements that is larger than one. We will calculate the signal to noise ratio of the signals as the peak-to-peak signal magnitude over the amplitude of the system background signal. The technical failure is that we will not be able to achieve measurements with signal-to-noise ratios larger than 1 in 10% of the measurements. We will have a futility analysis after first 5 patients are completed (thus 10 measurements). If of those 10 measurements, 2 have a SNR less 1, then the study will be stopped as it is unlikely to meet its 90% target.

    Time frame: day 1

Secondary outcomes

  1. Determining the ability to observe differences between benign and cancerous regions

    The secondary aim of this study is documenting our ability to observe differences between the PASA linear slope values derived from benign and cancerous regions, i.e., to detect the difference of 0.05 of 0.19, 0.17, 0.14, 0.20 dB/MHz between the means of the linear slopes in benign and cancerous regions at the wavelengths of 1220 nm, 1370 nm, 800 nm and 266 nm, respectively. We will aim at differentiating the measurements in benign and cancerous regions at specific wavelengths. We have a null hypothesis for each wavelength that at this specific wavelength, our measurement cannot differentiate the benign and cancerous regions. We will test the hypothesis with paired t-tests.

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2027, 48 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 48 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
Jul 28, 2023
StartActual
Oct 16, 2023
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 9, 2026
Study completion
Oct 2026→Oct 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05965180
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Oct 16, 2023
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Cancer AnswerLine
Contact
CancerAnswerLine@med.umich.edu
1-800-865-1125
Guan Xu, Phd
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion